Navigation Links
Vioxx and Celebrex, now have alternatives

Kingston: Researchers at Queen's University and the University of Pennsylvania have been able to zero in on a possible reason for drugs like Celebrex and Vioxx, administered for treatment// of pain and swelling that carry a potential risk of triggering a heart problem

Co-author Colin Funk, a professor of Biochemistry and Physiology at Queen's, and Canada Research Chair in Molecular, Cellular and Physiological Medicine has expressed optimism of finding a new league of anti-inflammatory drugs that will help tide over this side-effects issue. The success rate of testing it on mice is a fore runner to it being tested on humans. The study is published in the on-line edition of the Journal of Clinical Investigation.

Selective inhibitors of COX-2 such as Vioxx, Bextra and Celebrex carry an increased risk of heart attack and stroke; there has been in-depth study on comprehending the reasons for this occurrence. Co-author with Dr. Funk on the study is Dr. Garret FitzGerald, director of Penn's Institute for Translational Medicine and Therapeutics. Funding comes from the U.S. National Institutes of Health and a grant from Merck.

"The trials showed that COX-2 inhibitors confer a small, but absolute cardiovascular risk using the same mechanism by which they relieve pain and inflammation," Dr. Funk reports.

"Selective inhibitors of mPGES-1 may retain much of the benefit of drugs like Vioxx and Celebrex, while diminishing the risk of heart attack and stroke by having precisely the opposite effect on prostacyclin [a protective fat that Vioxx and Celebrex depresses]," says Dr. FitzGerald.

Source :Eureka
'"/>




Page: 1

Related medicine news :

1. Increased Heart Attack Risk From Celebrex,Vioxx
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Judgment In Favor Of Merck For Vioxx Drug
4. Could Long Tern Vioxx Users Suffer From Heart Attacks?
5. Doctor Grilled In Court For False Report About Vioxx Health Risk
6. Merck in the Dock Due To Vioxx
7. Vioxx Not Safe Even For Short Term Use
8. A Stroke of Bad Luck for Vioxx
9. Arcoxia Slammed –Nothing Better Than Vioxx Says FD
10. Increased Heart Attack Risk From Celebrex,Vioxx
11. Record growth of Soya-based dairy alternatives in Europe
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's ... goals for each and every seminar, session and class she offers. At ... brainwave tools which help energize creativity, focus mental functions, enhance athletic focus and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition of ... Qualis Health’s work is recognized across multiple award categories, highlighting four of the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
(Date:2/16/2017)... REDWOOD CITY, Calif. , Feb. 16, 2017 ... ), a specialty pharmaceutical company focused on the ... treatment of moderate-to-severe acute pain, announced that ... executive officer and a member of the company,s ... Mr. Angotti brings over two decades of experience ...
(Date:2/16/2017)... 16, 2017 Research and Markets has announced ... Analysis & Trends - Function, Application, Cancer Type, Technology - Forecast ... ... Market is poised to grow at a CAGR of around 28.6% ... Some of the prominent trends that the ...
Breaking Medicine Technology: